4-Pyrrolidin-1-ylmethyl-benzoyl chloride | 215649-27-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Pyrrolidin-1-ylmethyl-benzoyl chloride
• 英文别名: 4-(Pyrrolidin-1-ylmethyl)benzoyl chloride
• CAS: 215649-27-7
• 化学式: C₁₂H₁₄ClNO
• 分子量: 223.702
• InChiKey: BYUKNSIZQWJOMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Pyrrolidin-1-ylmethyl-benzoyl chloride 在 sodium azide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-(pyrrolidin-1-ylmethyl)benzoyl azide
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

  摘要：

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.001
• 作为产物：
  描述：

  4-(吡咯烷-1-甲基)苯甲酸甲酯 在 氯化亚砜 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 4-Pyrrolidin-1-ylmethyl-benzoyl chloride
  参考文献：
  名称：

  Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

  摘要：

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.001

文献信息

• New Acyl Derivatives of 3-Aminofurazanes and Their Antiplasmodial Activities
  作者：Theresa Hermann、Patrick Hochegger、Johanna Dolensky、Werner Seebacher、Robert Saf、Marcel Kaiser、Pascal Mäser、Robert Weis

  DOI：10.3390/ph14050412

  日期：——

  shown activity against different strains of Plasmodium falciparum. Seventeen new derivatives were prepared and tested in vitro for their activities against blood stages of two strains of Plasmodium falciparum. Several structure–activity relationships were revealed. The activity strongly depended on the nature of the acyl moiety. Only benzamides showed promising activity. The substitution pattern of their

  一项针对疟疾的药物风险投资（MMV）项目的N-酰化呋喃3胺已显示出对不同菌株恶性疟原虫的活性。制备了17种新的衍生物，并在体外测试了它们对两株恶性疟原虫血液阶段的活性。揭示了几种构效关系。活性强烈取决于酰基部分的性质。仅苯甲酰胺显示出有希望的活性。它们的苯环的取代方式影响化合物的活性和细胞毒性。另外，通过PAMPA计算（log P，log D，配体效率）或通过实验确定其物理化学参数（渗透率）。该ñ-（4-（3,4-二乙氧基苯基）-1,2,5-恶二唑-3-基）-3-（三氟甲基）苯甲酰胺具有良好的理化性质，对氯喹敏感菌株具有很高的抗血浆活性（IC 50（ NF54）= 0.019 µM）甚至更高的抗多重耐药菌株的抗疟原虫活性（IC 50（K 1）= 0.007 µM）。与MMV化合物相比，提高了通透性和抗多抗性菌株的活性。
• Diamino Benzo[<i>b</i>]thiophene Derivatives as a Novel Class of Active Site Directed Thrombin Inhibitors. 5. Potency, Efficacy, and Pharmacokinetic Properties of Modified C-3 Side Chain Derivatives
  作者：Daniel J. Sall、Dianna L. Bailey、Jolie A. Bastian、John A. Buben、Nickolay Y. Chirgadze、Amy C. Clemens-Smith、Michael L. Denney、Matthew J. Fisher、Deborah D. Giera、Donetta S. Gifford-Moore、Richard W. Harper、Lea M. Johnson、Valentine J. Klimkowski、Todd J. Kohn、Ho-Shen Lin、Jefferson R. McCowan、Alan D. Palkowitz、Michael E. Richett、Gerald F. Smith、David W. Snyder、Kumiko Takeuchi、John E. Toth、Minsheng Zhang

  DOI：10.1021/jm9903388

  日期：2000.2.1

  A systematic investigation of the structure-activity relationships of the C-3 side chain of the screening hit la led to the identification of the potent thrombin inhibitors 23c, 28c, and 31c. Their activities (1240, 903, and 1271 x 10(6) L/mol, respectively) represent 2200- and 2900-fold increases in potency over the starting lead la. This activity enhancement was accomplished with an increase of thrombin selectivity. The in vitro anticoagulant profiles of derivatives 28c and 31c were determined, and they compare favorably with the clinical agent H-R-1-[4aS,-8aS]perhydroisoquinolyl-prolyl-arginyl aldehyde (D-Piq-Pro-Arg-H; 32). The more potent members of this series have been studied in an arterial/venous shunt (AV shunt) model of thrombosis and were found to be efficacious in reducing clot formation. However, their efficacy is currently limited by their rapid and extensive distribution following administration.
• Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR–ABL kinase inhibitors
  作者：Liming Hu、Yuyan Zheng、Zhipeng Li、Yujie Wang、Yongjuan Lv、Xuemei Qin、Chengchu Zeng

  DOI：10.1016/j.bmc.2015.04.083

  日期：2015.7

  4-(Pyridin-3-yl)-1H-pyrazol-1-yl-phenyl-3-benzamide derivatives have been proposed as new BCR-ABL tyrosine kinase inhibitors by using combinational strategies of scaffold hopping and conformational constraint. In the present study, a series of 4-(pyridin-3-yl)-1H-pyrazol-1-yl-phenyl-3-benzamide derivatives were synthesized and their activities against BCR-ABL1 kinase in vitro were evaluated by using Kinase-Glo assay. All new compounds showed from moderate to potent activities against wild-type (wt) BCR-ABL1 kinase with an IC50 range from 14.2 to 326.0 nM. Among them, seven compounds exhibited BCR-ABL1 kinase inhibitory activities with IC50 values less than 50 nM. Compound 7a displayed the most potent inhibitory activity to BCR-ABL kinase (IC50: 14.2 nM). Docking simulation was performed for compounds 7a and 7i into the BCR-ABL kinase structure active site to determine the probable binding model. The preliminary structure-activity relationship was discussed. The interesting activities of these compounds may make them promising candidates as therapeutic agents for chronic myelogenous leukemia. (C) 2015 Elsevier Ltd. All rights reserved.
• Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors
  作者：Ru Dong、Xin Zhou、Min Wang、Wen Li、Jin-Yang Zhang、Xin Zheng、Kai-Xiang Tang、Li-Ping Sun

  DOI：10.1016/j.bmc.2020.115876

  日期：2021.1
• Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents
  作者：Sai-Jie Zuo、Sai Zhang、Shuai Mao、Xiao-Xiao Xie、Xue Xiao、Min-Hnag Xin、Wei Xuan、Yuan-Yuan He、Yong-Xiao Cao、San-Qi Zhang

  DOI：10.1016/j.bmc.2015.12.001

  日期：2016.1

  In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.